Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Percheron Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Antisense commences trial dosing, Shine lawyers deliver historic $300m settlement
Health & Biotech
Check Up: As the pandemic winds down, what’s happening with Covid focused biotechs?
Health & Biotech
ASX Health Stocks: Big announcements as Invex and Antisense jump over 20pc this morning
Experts
ScoPo’s Powerplays: ASX health stocks up for second week, investors get reason to smile
Health & Biotech
ScoPo’s Powerplays: ASX health stocks show signs of jittery recovery
Health & Biotech
ASX Health Stocks: Antisense says ATL1102 could be effective in rare genetic muscle disease
Health & Biotech
ASX Health Stocks: NeuroScientific gains on study news; FDA report gives Auscann a boost
Health & Biotech
ASX Health Stocks: Virtus is being pursued as Bionomics prepares for dual Nasdaq listing
Health & Biotech
ASX Health Stocks: Aussie biotechs Argenica and Antisense take major steps in the US
Health & Biotech
ASX Health Stocks: Visioneering jumps 13pc on contact lenses launch, Sigma drops bid for API
Health & Biotech
Check Up: Fundie says ‘buy the dip’ as biotech loses shine amid pandemic rebound
Health & Biotech
ASX Health Stocks: Zelira shares jump on $4m cannabis distribution deal to Germany
News
10 at 10: These ASX stocks are getting the strongest reception this morning
Health & Biotech
ScoPo’s Powerplays: Solid earnings for health stocks all round, but price action stays with larger caps
Health & Biotech
The surge and plunge in ASX biotech shows what the FDA giveth, the FDA taketh away
News
ScoPo’s Powerplays: Mental health takes centre stage; Actinogen to progress Alzheimer’s study
News
